AnalystBro Research
Research
Company valuation reports, peer comparisons, results notes, industry reports and macro views, built from company filings and official data and independently reviewed before publishing. Company reports show their full model as view-only sheets. Facts and estimates, not investment advice.
2 articles.
Bangladesh All Bangladesh research →
Company · DSE:SAMORITA · Pharma & healthcare · Analysis · 01 Nov 2026
Samorita Hospital: revenue BDT 401.4m in FY2025, land BDT 884.3m on the balance sheet, FY2026 EPS BDT 1.12
Revenue reached BDT 401.4m in FY2025 and the DSE-announced FY2026 EPS rose to BDT 1.12 from 0.62; net margin has stayed between 0.2% and 4.8% since FY2022, the auditor qualified the FY2025 accounts on WPPF and gratuity, and the stock trades at 74x FY2026 EPS and 1.71x NAV.
Company · DSE:JHRML · Pharmaceuticals & healthcare (medical devices) · Analysis · 31 Oct 2026
JMI Hospital Requisite: device sales fell 10.7% in FY2025 and a new hospital cut FY2026 EPS to BDT 0.71; BDT 745m is lent to sister companies
Revenue fell from BDT 1,870m to 1,671m in FY2025 and 9M FY2026 sales were 6.1% lower again; the Apollo-licensed hospital opened in August 2025 and lost about BDT 81m in nine months. Interest charged to group companies was 30% of FY2025 pre-tax profit.